FDA grants priority review to ripretinib for advanced gastrointestinal stromal tumors

The FDA granted priority review to ripretinib for treatment of advanced gastrointestinal stromal tumors, according to a press release from the agent’s manufacturer.Ripretinib (Deciphera Pharmaceuticals) is a tyrosine kinase switch control inhibitor engineered to broadly inhibit KIT and platelet-derived growth factor receptor alpha-mutated kinases.The FDA previously granted fast track and breakthrough therapy designations to the agent for use by patients with previously treated advanced gastrointestinal stromal tumors (GIST).The agency is expected to make a decision on the new drugRead More

Share on facebook
Share on twitter
Share on linkedin